Amneal Pharmaceuticals (AMRX) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Do analysts rate ASND or AMRX?

Ascendis Pharma A/S presently has a consensus target price of $192.07, suggesting a potential upside of 49.90%. Amneal Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 21.07%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Which has better earnings and valuation, ASND or AMRX?

Amneal Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$288.08M	26.99	-$521.07M	-$8.08	-15.86
Amneal Pharmaceuticals	$2.39B	1.07	-$83.99M	-$0.68	-12.15

Is ASND or AMRX more profitable?

Amneal Pharmaceuticals has a net margin of -6.88% compared to Ascendis Pharma A/S's net margin of -130.33%. Ascendis Pharma A/S's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-130.33%	N/A	-48.77%
Amneal Pharmaceuticals	-6.88%	-346.26%	4.85%

Do insiders & institutionals have more ownership in ASND or AMRX?

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Does the media prefer ASND or AMRX?

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 10 mentions for Ascendis Pharma A/S. Amneal Pharmaceuticals' average media sentiment score of 0.65 beat Ascendis Pharma A/S's score of 0.64 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	2 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor ASND or AMRX?

Ascendis Pharma A/S received 424 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 94.12% of users gave Amneal Pharmaceuticals an outperform vote while only 66.57% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 440 66.57%	Underperform Votes 221 33.43%
Amneal Pharmaceuticals	Outperform Votes 16 94.12%	Underperform Votes 1 5.88%

Which has more volatility and risk, ASND or AMRX?

Ascendis Pharma A/S has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.

Summary

Amneal Pharmaceuticals beats Ascendis Pharma A/S on 11 of the 18 factors compared between the two stocks.